Close

Pfizer (PFE) Says FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

June 7, 2018 8:00 AM EDT Send to a Friend
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration accepted for filing and granted Priority Review ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login